PharmacoFore secures $10M Series B to advance "next generation" abuse resistant opioids, plus propofol alternative
This article was originally published in Scrip
Executive Summary
PharmacoFore Inc, a privately held development-stage company, has secured a $10 million Series B round of financing from the Founders Fund to advance its business model of improving upon the therapeutic utility of certain existing drugs and developing abuse-resistant opioids. It is also developing an alternative to propofol.